Form D · Biotechnology

Diceros Therapeutics, Inc.

Newton, MA · CIK 0001948469

Offering snapshot reported Aug 5, 2024 · SEC filing

Reported sold
$12.6M
Offering amount: $18.1M
Investors reported
13
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Sep 19, 2022
As reported in this filing

Fundraising history

Reported sold
Reported amount sold by Form D filing date$0$6.3M$12.6MSep 30, 2022: $6,679,992.00Sep 30, 2022Aug 5, 2024: $12,609,962.00Aug 5, 2024

Dates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.

What changed?

Latest filing versus its linked predecessor, where available.

  • Reported sold$6,679,992 → $12,609,962

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Aug 5, 2024Amendment$12,609,962$5,929,970vs Sep 30, 202213SEC filing
Sep 30, 2022Initial$6,679,992No comparison13SEC filing

Offering details

Securities
Equity, Option to acquire
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-460347

Source: Form D, filed Aug 5, 2024. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Jonathan Fleming Director
Wyatt Gotbetter Director
Stephen R. Seiler Director, Executive
Ids Van Der Weij Director

Issuer details

Industry: Biotechnology (See others in industry)

Address:
275 Grove Street, 2 400
Newton, MA, 02466